The question of drug combinations for consolidation and maintenance for multiple myeloma
What does the TOURMALINE-MM2 study tell us about the use of ixazomib in multiple myeloma?
Idelalisib plus bendamustine and rituximab improves the outcome of relapsed/refractory CLL
Treatment options for patients with advanced multiple myeloma
Recent drug approvals for the treatment of relapsed/refractory multiple myeloma